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Abstract: A contributing factor in the development of ulcerative colitis (UC) and Crohn’s disease
(CD) is the disruption of innate and adaptive signaling pathways due to aberrant cytokine production.
The cytokine, interleukin (IL)-1β, is highly inflammatory and its production is tightly regulated
through transcriptional control and both inflammasome-dependent and inflammasome- independent
proteolytic cleavage. In this study, qRT-PCR, immunohistochemistry, immunofluorescence confocal
microscopy were used to (1) assess the mRNA expression of NLRP3, IL-1β, CASP1 and ASC in paired
biopsies from UC and CD patient, and (2) the colonic localization and spatial relationship of NLRP3
and IL-1β in active and quiescent disease. NLRP3 and IL-1β were found to be upregulated in active
UC and CD. During active disease, IL-1β was localized to the infiltrate of lamina propria immune
cells, which contrasts with the near-exclusive epithelial cell layer expression during non-inflammatory
conditions. In active disease, NLRP3 was consistently expressed within the neutrophils and other
immune cells of the lamina propria and absent from the epithelial cell layer. The disparity in
spatial localization of IL-1β and NLRP3, observed only in active UC, which is characterized
by a neutrophil-dominated lamina propria cell population, implies inflammasome-independent
processing of IL-1β. Consistent with other acute inflammatory conditions, these results suggest
that blocking both caspase-1 and neutrophil-derived serine proteases may provide an additional
therapeutic option for treating active UC.
Keywords: NLRP3 inflammasome; Interleukin (IL)-1β; ulcerative colitis (UC); Crohn’s disease (CD);
innate immune system
1. Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are characterized by chronic and relapsing
inflammation of the gastrointestinal tract and are collectively known as inflammatory bowel diseases
(IBD). Patients are usually first diagnosed during adolescence or early adulthood and in general
present with symptoms of diarrhea, rectal bleeding, abdominal pain, and malnutrition [1]. IBD is
regarded as a multifactorial disease process involving a combination of innate immune system defects
and environmental triggers which occur in the genetically predisposed individual [2].
Important to innate immune defenses is the induction, production, and release of proinflammatory
cytokines, which direct an effective host defense, and subsequent modulation of the adaptive immune
response. One member of the IL-1 family of cytokines, IL-1β is considered highly inflammatory [3]
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and classified as a multifunctional cytokine. IL-1β participates in local and systemic responses to
injury, infection, and inflammation. Clinically, IL-1β can evoke fever and hypotension [4], and control
certain central nervous system functions such as sleep, pain, and appetite [5]. Locally, IL-1β can induce
cytokine production, enhance T cell activation and antigen recognition, and direct neutrophils to the
site of injury or infection [6–8].
IL-1β is produced as an inactive 31kDa proIL-1β protein in response to Toll-like receptor
(TLR) activation and enzymatic cleavage is required to generate a bioactive 17kDa IL-1β fragment.
The synthesis of a precursor cytokine requiring activation by proteases prevents aberrant secretion of
IL-1β [9].
Several inflammasomes such as, NLRP1, NLRP3, NLRC4, NLRP6, NLRP7, NLRP12, AIM2 and
IFI16 have been described for the canonical activation of caspase-1 and maturation of IL-1β [10].
Inflammasome activation is regarded as a two-step process. Transcription and translation of
inflammasome components precedes the ligand activation step, which culminates in the assembly
of the inflammasome platform and the maturation of IL-1β [11,12]. Important to innate immune
defenses is the formation of the NLRP3 inflammasome which occurs in response to a wide range of
microbial, environmental, and sterile ligands [10,13]. While the exact mechanisms of ligand activation
are yet to be determined it is generally accepted that assembly of the NLRP3 inflammasome occurs
in response to host derived factors altered by these agents. The indirect mechanisms include K+
efflux [14], phagolysosmal destabilization and release of cathepsins [15], the release of mitochondrial
DNA or the mitochondrial phospholipid cardiolipin [16–18], translocation to the mitochondria [19–21]
or the presence of mitochondrial derived reactive oxygen species (mROS) [19].
In addition to inflammasome-dependent production of IL-1β, several cell specific
inflammasome-independent processes exist for the activation of IL-1β. IL-1β is a primary product of
blood monocytes, tissue macrophages, neutrophils, dendritic cells and to a lesser extent, B lymphocytes
and Natural Killer cells [22]. In blood monocytes, caspase-1 is constitutively expressed and the
production of active IL-1β occurs via transcriptional control. This mechanism is thought to aid host
defenses by reducing immune response time [23].
The zinc-dependent metalloproteinases, meprin A and meprin α are highly expressed at
the brush-border membranes of the kidney and intestine, and can generate biologically active
IL-1β [24]. During acute inflammation, neutrophil and macrophage derived serine proteases,
proteinase 3, elastase and cathepsin G can process proIL-1β to biologically active IL-1β [23,25–27].
Indeed, microbes such as Candida albicans and Staphylococcus spp. can themselves produce proteases,
which possess the ability to cleave proIL-1β [28,29]. Despite this, the dependence of NLRP3 to IL-1β
production has not been investigated in human UC or CD biopsy material, and therefore the aim of this
study was to investigate the NLRP3 inflammasome and its cleavage product, IL-1β in active disease.
2. Results
2.1. Clinical Characteristics of IBD Cohort
The control group for this study included mucosal biopsies from 20 healthy patients who
underwent routine colonoscopy investigations. The mean age of the control group was 57 ± 14
and comprised 11 females and 9 males.
The UC cohort included 44 patients, of these 27 (61%) were taking prescription medication to
control their disease while 17 patients (39%) were untreated. Most UC patients were prescribed 5-ASAs
81% (22/27) with 50% (11/22) of 5-ASAs users also taking a defined tapering course of corticosteroids
for an active flare of disease (Table 1).
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Table 1. Clinical characteristics of ulcerative colitis patients.
Variable
Patients with Active Disease Patients in Remission
Biopsies Taken from both
Active and Inactive Regions
Biopsies Taken from
Active Regions only
Biopsies Taken from
Inactive Regions
Patients, n 30 4 10
Age (years) 50 ± 18 39 ± 21 49 ± 11
Gender
female 16 2 6
male 14 2 4
Smoker, n (%) 1 (3) 0 1 (10)
Disease extent *
Proctitis only 7 (23) - -
Proctosigmoiditis 14 (47) - -
Left-sided colitis 8 (27) - -
Pancolitis 1 (3) 4 (100) 4 (100)
Current Medication for UC
Untreated 12 (40) 2 (50) 3 (30)
Aminosalicylates (5-ASA) 16 (53) 1 (25) 5 (50)
Corticosteroids 6 (20) 2 (50) 3 (30)
Immunomodulator therapy 4 (13) - -
Topical therapy 0 - -
Biologic therapy 0 - -
Antibiotics/probiotics/vitamin
supplements 6 - 1
Age and disease duration data are shown as mean value ± SD. Other data indicates the number of patients. Group
percentages are shown in brackets. * Disease Extent: Proctitis: Disease only in the rectum; Proctosigmoiditis:
Disease in the rectum and sigmoid colon; Left-sided colitis: Limited or distal colitis. Disease in left side of the colon;
Pancolitis: Disease in the entire colon.
The CD cohort included 21 patients, of these 16 patients (76%) were being treated with prescription
medication, while 5 patients (24%) were untreated at time of biopsy collection. Medication regimes
favored 5-ASAs (29%, 6/21) and immunomodulators (29%, 6/21) while there was less use of
corticosteroids (10%, 2/21) and biologic agents (19%, 4/21) (Table 2). As expected, there was a higher
proportion of smokers in the CD group (24%, 5/21) when compared to the UC group (5%, 2/44).
Table 2. Clinical characteristics of Crohn’s disease patients.
Variable
Patients with Active Disease Patients in Remission
Biopsies Taken from both
Active and Inactive Regions
Biopsies Taken from
Active Regions only
Biopsies Taken from
Inactive Regions
Patients, n 15 2 4
Age (years) 44 ± 16 37 ± 13 20 ± 7
Gender
female 7 1 3
male 8 1 1
Smoker, n (%) 4 (27) 0 1 (25)
Disease extent *
Ileum only (L1) 4 (27) 1 -
Ileum and colon (L3) 2 (13) - -
Colon only (L2) 9 (60) 1 -
Extra-intestinal manifestations (e.g.,
ileocecal/perianal/proctitis) 4 (27) - -
Previous surgical resection 4 (27) - 1
Current Medication for CD
Untreated 4 (27) - 1 (25)
Aminosalicylates (5-ASA) 5 (33) - 1
Corticosteroids 2 (13) - -
Immunomodulator therapy 6 (40) 1 1
Topical therapy - - -
Biologic therapy 2 (13) 1 1
Antibiotics/probiotics/vitamin
supplements - - -
Age and disease duration data are shown as mean value ± SD. Other data indicates the number of patients. Group
percentages are shown in brackets. Montreal CD classifications; L1, terminal ileum involvement; L2, colonic disease;
L3 ileocolonic involvement. * Disease Extent: Extra-intestinal manifestations (e.g., ileocecal/perianal/proctitis)
included as a separate section but can co-exist with colonic and ileum manifestations.
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2.2. NLRP3 and IL-1β Are Upregulated in Active Disease
Using paired human colonic biopsies from quiescent and active UC and CD, we began by
investigating the mRNA expression of NLRP3 inflammasome related genes using quantitative
real-time-polymerase chain reaction (qRT-PCR). The expression of NLRP3 and IL-1β were found
to increase with disease activity in both UC and CD (Table 3, Figure 1A,B). Consistent with NLRP3
inflammasome activation the expression of CASP1 and ASC also increased (Table 3, Figure 1C,D).
Correlation analysis of mRNA expression revealed a stronger correlation with IL-1β in active CD (Rs =
0.96, p < 0.01) (Figure 1F) than in active UC (Rs = 0.78, p < 0.01) (Figure 1E).
Table 3. Relative expression of NLRP3 related genes in IBD.
TargetGene Disease Phenotype
Quiescent Disease Active Disease
p
Median R.E IQR Median R.E IQR
NLRP3
UC # 1.5 1.0–2.3 3.7 2.5–5.7 <0.001
CD ˆ 1.6 0.9–2.8 5.2 2.9–15.1 <0.001
IL-1β UC
# 2.2 0.8–5.9 28.1 13.2–78.7 <0.001
CD ˆ 4.1 1.5–7.0 55.1 17.2–215.7 <0.001
CASP1
UC # 1.3 0.8–2.3 5.1 2.9–9.3 <0.001
CD ˆ 2.5 0.9–3.9 6.9 4.5–10.2 <0.001
ASC
UC # 1.0 0.5–1.7 4.8 2.3–9.2 <0.001
CD ˆ 1.3 0.7–2.8 3.5 1.9–16.9 0.001
Quantitative RT-PCR was used to determine the expression of inflammasome related genes in IBD. Median Relative
Expression (R.E) and interquartile ranges (IQR) are relative to the control group and normalized to the housekeeping
gene EEF2. Group differences were tested using Mann-Whitney test of log (10) transformed data. The significance
threshold was p < 0.05. # Column statistics for UC patients; quiescent disease, n = 40, active disease, n = 34; group
difference, n = 30, ˆ Column statistics for CD patients; quiescent disease, n = 19; active disease, n = 17, Group
differences, n = 15.
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Figure 1. Gene expression and correlation of NLRP3 inflammasome related genes in paired biopsies
from quiescent UC (qUC), active UC (aUC), quiescent CD (qCD) and active. CD (aCD). The mRNA
expression of (A) NLRP3, (B) IL-1β, (C) CASP1, and (D) ASC was compared to a healthy control
group and normalized to the housekeeping gene, EEF2. Individual patient results are shown as dots.
Horizontal lines indicate the median relative expression (R.E) and error bars represent the interquartile
ranges. Group differences were tested using Mann-Whitney test of log10 transformed data. E) The
correlation of NLRP3 and IL-1β mRNA in active UC. F) The correlation of NLRP3 and IL-1β mRNA in
active UC. The significance threshold was p < 0.05.
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2.3. NLRP3 is Localized to the Influx of Lamina Propria Cells in Active UC
We next sought to determine the cellular localization of NLRP3 and IL-1β in active and remission
IBD by using immunohistochemistry. The expression of NLRP3 was found to increase with disease
activity in both active UC and active CD. For active UC, prominent cytoplasmic staining was evident
in the neutrophils and other immune cells of the lamina propria while diffuse staining was evident in
the epithelial cell region. Consistent with pathology reports, biopsy sections from active UC patients
were characterized by an influx of lamina propria immune cells concentrated around regions of crypt
distortion or mucosal inflammation (Figure 2, black dotted box indicates increased numbers of lamina
propria neutrophils).Int. J. Mol. Sci. 2018, 19, x 6 of 16 
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Figure 2. Representative immunohistochemistry images of NLRP3 expression in normal colon,
active UC, remission UC, active CD and remission CD. All biopsies were taken from the left colon
(unless otherwise stated as ileum biopsy), paraffin embedded, cut into 5 µm sections and incubated
with NLRP3 (ab17267, Abcam, Cambridge, MA, USA) at a dilution of 1:300. Disease diagnosis was
confirmed by a practicing pathologist. Black dotted box indicates increased numbers of lamina propria
neutrophils in active UC. Scale bars represent 200 µm for 100× and 50 µm for 400×magnification.
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For active CD, the reported influx of lamina propria immune cells seen in active UC was not
evident; however, the intensity of staining for NLRP3 within the lamina propria immune cells was
comparable. Moderate cytoplasmic staining for NLRP3 was also evident in the epithelial cell layer
including around goblet cells.
In the normal colon, remission UC and remission CD only scattered NLRP3 staining was evident
in a lamina propria immune cells. Quantitative analysis of immunohistochemistry staining confirmed
the increased expression of NLRP3 in active UC (p < 0.001) and active CD (p = 0.007) (Figure 4A).
Interestingly, expression of NLRP3 in remission UC and remission CD are similar to that observed in
the normal colon.
In normal colon biopsies, high expression of IL-1β was observed within the epithelial cell layer
of the mucosal crypts, including the cytoplasm of intestinal goblet cells. For active UC and active
CD high IL-1β expression was predominantly localized to the immune cells of the lamina propria
and scattered within the epithelial cell layer (Figure 3). Quantitative analysis confirmed the increased
expression of IL-1β in active UC (p < 0.001) and active CD (p = 0.006). Notably, the expression of IL-1β
in remission UC was less than that observed in the normal colon (p = 0.003) (Figure 4B).
Int. J. Mol. Sci. 2018, 19, x 7 of 16 
 
Interestingly, expression of NLRP3 in remission UC and remission CD are similar to t at observed in 
the normal colon. 
In normal colon biopsies, high expression of IL-1β was observed within the epithelial cell layer 
of the mucosal crypts, including the cytoplasm of intestinal goblet cells. For active UC and active CD 
hig  IL-1β xpression was predominantly localized to the immune cells of the lamina propria and 
scattered within the epithelial cell layer (Figure 3). Quantitative analysis confirmed the increased 
expression of IL-1β in active UC (p < 0.001) and active CD (p = 0.006). Notably, the expression of IL-
1β in remission UC was less than that observed in the normal colon (p = 0.003) (Figure 4B). 
 
Figure 3. Representative immunohistochemistry images of IL-1β expression in normal colon, active 
UC, remission UC, active CD and remission CD. All biopsies were taken from the left colon 
(unless stated as ileum biopsy), paraffin embedded, cut into 5 μm sections and incubated 
with IL-1β (ab9722, Abcam, Cambridge, MA, USA) at a dilution of 1:300. Disease diagnosis 
Figure 3. Representative immunohistoc emistry images IL-1β expression in n rm l colon, active
UC, remission UC, active CD and remission CD. All biopsies were taken from the left colon (unless
stated as ileum biopsy), paraffin embedded, cut into 5 µm sections and incubated with IL-1β (ab9722,
Abcam, Cambridge, MA, USA) at a dilution of 1:300. Disease diagnosis was confirmed by a practicing
pathologist. Scale bars represent 50 µm for 400× and 200 µm for 100×magnification.
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Figure 4. Quantification of NLRP3 and IL-1β IHC staining in biopsies sections from normal and
IBD patients. (A) Quantitative analysis of NLRP3 expression in sections from normal colon (total
number of images analyzed = 10), active UC (n = 91), remission UC (Rem. UC, n = 21), active CD
(n = 42), and remission CD (Rem. CD, n = 18). (B) Quantitative analysis of IL-1β expression in sections
from normal colon (n = 24), active UC (n = 46), remission UC (Rem. UC, n = 20), active CD (n = 64),
and remission CD (Rem. CD, n = 18). Paraffin embedded left colon mucosal biopsies were analyzed
by i munohistochemistry nd the optical intensity of DAB staining due t primary antibody was
determined using FIJI software. All data are presented as me n ± standard deviation. Statistical
significance was evaluated using Dunn’s multiple comparison one-way analysis of variance (ANOVA).
The significance threshold was p < 0.05.
2.4. The Contribution of NLRP3 to IL-1β Is Reduced in Active UC
The concurrent expression of NLRP3 and IL-1β within the lamina propria cell populations
in active disease prompted a detailed colocalization analysis using immunofluorescence confocal
microscopy. Mand rs coefficients (M1 and M2) were used to evaluate the reciprocal association rati
betwe n fluorescenc m rkers with values ranging from 0.5 to 1.0 indicating a positive associati .
Pearson’s correlation coefficient was used to describe the correlation of the intensity distribution
between channels. Values range from -1 to 1 and indicate the strength of the negative or positive
correlation [30]. For normal colon, a high proportion of colocalization between NLRP3 and IL-1β was
evident within the lamina propria immune cells (Figure 5).
Quantification of Manders coefficients confirmed a positive association between NLRP3 and IL-1β
(M1, NLRP3:IL-1β = 0.81 ± 0.06; M2, IL-1β:NLRP3 = 0.82 ± 0.06) indicating a similar contribution of
one to the other (Figure 6A).
Manders coefficients demonstrated less colocalization of NLRP3 to IL-1β in active UC (M1,
NLRP3:IL-1β = 0.67 ± 0.04; M2, IL-1β:NLRP3 = 0.61 ± 0.09) (Figure 6B) when compared to normal
colon biopsies. Interestingly, the appearance of a y-dominated scattergram suggests increased IL-1β
production without concomita t and spatially coincident i creases in NLRP3 (Figure 5). The lack
of correlation between NLRP3 and IL-1β in active UC is confirmed by the near zero (0.03) Pearson
correlation coefficient (Figure 6D).
For active CD, the colocalization of NLRP3 and IL-1β (M1, NLRP3: IL-1β = 0.78 ± 0.05; M2,
IL-1β:NLRP3 = 0.80 ± 0.05; Pearson’s correlation coefficient = 0.29) was similar to that seen in the
normal colon (Figure 6C,D).
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research in human derived material [31–35]. In normal colon, IL-1β was localized to the epithelial 
layer and generally absent from the lamina propria immune cells, while NLRP3 expression was 
generally present at low levels in the lamina propria immune cells. With disease activity, the 
expression of IL-1β shifted from the epithelial cell layer to the lamina propria cells and the expression 
of both NLRP3 and IL-1β in the lamina propria immune cells intensified. Previously, NLRP3 
expression has been demonstrated in granulocytes, such as neutrophils, dendritic cell, monocytes, 
epithelial cells, T cells and B cells, with subcellular distribution localization mainly in the cytoplasm 
[36].  
We observed increased numbers of neutrophils in the lamina propria of active UC patients 
which was consistent with pathology histology reports. The composition of the lamina propria 
infiltrates, microscopic architectural abnormalities and inflammatory changes are all important 
features for discriminating normal mucosa from IBD [37]. During active UC, neutrophils dominate 
the lamina propria immune cell population and are often the effector cells surrounding epithelial 
Figure 6. The colocalization of NLRP3 and IL-1β in nor al and active disease as indicated by Manders
colocalization coefficients and Pearson’s correlation coefficients. Each data set was compiled from
lamina propria regions of interest (ROI), 400× images from (A) normal colon (n = 20), (B) active UC
(n = 20), (C) active CD (n = 20). Manders coefficients (M1 and M2) were used to evaluate the reciprocal
association ratio between fluorescence markers. (D) The Pearson’s correlation coefficient describes the
fluorescence intensity distribution between the channels. Averages are presented as mean + standard
deviation. Significance was tested using one-way ANOVA followed by Tukey’s multiple comparison
test. The significance threshold was p < 0.05.
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3. Discussion
This study demonstrates the upregulation of NLRP3 and IL-1β in active IBD and describes the
colonic localization of NLRP3 and IL-1β in active and remission disease. Furthermore, the increase in
IL-1β production without concomitant and spatially coincident increases in NLRP3 observed only in
active UC, and in a background of a dominated neutrophilic lamina propria cell population suggests
inflammasome-independent processing of IL-1β.
The inflammasome complex is a key regulator of IL-1β production. The demonstrated increase
in IL-1β gene expression in both active UC and CD is well established and consistent with previous
research in human derived material [31–35]. In normal colon, IL-1β was localized to the epithelial layer
and generally absent from the lamina propria immune cells, while NLRP3 expression was generally
present at low levels in the lamina propria immune cells. With disease activity, the expression of IL-1β
shifted from the epithelial cell layer to the lamina propria cells and the expression of both NLRP3
and IL-1β in the lamina propria immune cells intensified. Previously, NLRP3 expression has been
demonstrated in granulocytes, such as neutrophils, dendritic cell, monocytes, epithelial cells, T cells
and B cells, with subcellular distribution localization mainly in the cytoplasm [36].
We observed increased numbers of neutrophils in the lamina propria of active UC patients which
was consistent with pathology histology reports. The composition of the lamina propria infiltrates,
microscopic architectural abnormalities and inflammatory changes are all important features for
discriminating normal mucosa from IBD [37]. During active UC, neutrophils dominate the lamina
propria immune cell population and are often the effector cells surrounding epithelial damage
or mucosal inflammation [38]. Consequently, many grading scales for histological assessment of
inflammation in UC include the presence and locality of neutrophils [39–41]. Furthermore, the use of
neutrophils as a marker of disease activity in UC is supported by leucocyte scanning studies [42,43].
The lack of acceptable sensitivity, specificity, and reproducibility discourages diagnosis of CD
based on the lamina propria infiltrate. Diagnosis of CD therefore relies on the presence of epithelioid
granuloma, relatively unchanged crypts or segmented distribution of crypt atrophy, crypt distortion
together with discontinuous focal or patchy inflammation (skip lesions) and mucin preservation in
the epithelium at an ulcer edge. Focal inflammation is often characterized by a small collection of
inflammatory cells in otherwise normal mucosa [44–46]. Microscopic structural abnormalities and the
influx of lamina propria immune cells are not features of normal mucosa.
We report reduced colocalization between NLRP3 and IL-1β in active UC when compared to
active CD and normal mucosa biopsies, suggesting NLRP3 inflammasome-independent mechanisms
contribute more to the overall IL-1β production in active UC. Inflammasome-independent processing
of proIL-1β in acute inflammatory conditions is well established and has been shown to occur where
neutrophils dominate the lamina propria cell populations. For instance, host resistance to disseminated
candidiasis is provided by neutrophil-derived proteinase 3 activation of IL-1β and not caspase-1
activation [29,47,48]. Similarly, during acute arthritis, neutrophil-derived proteinase 3 plays a dominant
role in in the production of bioactive IL-1β [49]. Again, serine proteases from neutrophils drive the
inflammation and production of mature IL-1β in a murine model of osteomyelitis [50,51].
The blockade of NLRP3 using selective small-molecule inhibitors has recently been the focus of
much research. MCC950 has been shown to inhibit canonical and non-canonical NLRP3 inflammasome
activation and reduce IL-1β production [52]. However, based on the results from this study, in diseases
such as UC where neutrophils dominate the lamina propria infiltrate, blocking NLRP3 or caspase-1
may not reduce in vivo IL-1β levels.
In summary, the results of this study suggest that during normal gut homeostasis
inflammasome-dependent caspase-1 is a major contributor to IL-1β production. However, during
active UC when neutrophils dominate the lamina propria maturation of IL-1β by neutrophil
deriver serine proteases may contribute more to IL-1β production than inflammasome-dependent
caspase-1 cleavage.
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The dual blockage of both caspase-1 and proteinase 3 is seen as a potential anti-inflammatory
therapeutic option in a murine model of arthritis [49]. Likewise, future IBD research should now
focus on assessing neutrophil-derived IL-1β production and the therapeutic potential of blocking both
caspase-1 and neutrophil-derived serine proteases in active UC.
4. Materials and Methods
4.1. Ethics
The study was conducted at the University of Tasmania, in collaboration with local
gastroenterologists, St Vincent’s Private Hospital and Launceston General Hospital. Human studies
were approved by the Human Research Ethics Committee, Tasmania (approval number: H11930,
19 October 2011). All participant in this study provided informed written consent or parental
consent and were aged between 15 and 80 years. All authors had access to the study data, reviewed,
and approved the final manuscript.
4.2. Study Participants and Biopsy Collection
A total of 85 patients presenting for routine colonoscopy investigations between June 2012
and June 2014 were recruited for this study. IBD patients were excluded if they were experiencing
co-existing irritable bowel syndrome (IBS) or non-IBD associated gastrointestinal bleeding at the
time of colonoscopy. IBD patients had paired colonic biopsies taken from both inflamed mucosa and
non-inflamed mucosa. Control patients were excluded if they had a previous history of IBD or IBS.
Of the 85 participants, 30 UC patients and 15 CD patients had colonic biopsies taken from both
inflamed mucosa and non-inflamed mucosa. Ten UC patients and four CD patients were in remission
at the time of colonoscopy and only had biopsies taken from non-inflamed mucosa. Four UC and two
CD patients presented with pancolonic disease and had biopsies taken from inflamed mucosa only.
Twenty control patients had biopsies collected from healthy non-inflamed mucosa.
Disease assessment and biopsy location was at the discretion of the treating gastroenterologist
(Mark Veldhuis, Brent Mitchell and Scott Fanning). Selection for immunohistochemistry or
immunofluorescence microscopy analysis was based on patient pathology reports and only biopsies
from the descending left colon with active disease features were chosen.
4.3. Gene Expression Analysis
Total RNA was extracted from tissue biopsies using the RNeasy Plus Mini Kit (QIAGEN, Venlo,
Netherlands). RNA quality and concentration were determined using the Experion automated
electrophoresis system (BIO-RAD, Hercules, CA, USA). RNA was reverse transcribed to cDNA using
the iScript cDNA synthesis kit (BIO-RAD, Hercules, CA, USA). Quantitative real-time-polymerase
chain reaction (qRT-PCR) was performed on a StepOne analyzer (Applied Biosystems, CA, USA) using
a TaqMan Universal PCR Master mix (Applied Biosystems, CA, USA) and on-demand gene-specific
primers for human IL-1β, NLRP3, CASP1 and ASC. Gene expression was quantified using the
comparative (∆∆Ct) method where the threshold cycle (CT) was normalized to the reference gene,
eukaryotic translation elongation factor (EEF2).
4.4. Immunohistochemistry Analysis
Immunohistochemistry was performed on 10% (v/v) formalin fixed, paraffin embedded left colon
biopsies. Sections were deparaffinized and subjected to 0.01 M citrate buffer (pH 6.0) antigen retrieval
at 121 ◦C for 4 min in a decloaking chamber. Endogenous peroxidases were quenched by a 5-min
incubation in 10% H2O2 in methanol. Non-specific binding was blocked by a 20-min incubation in
BioCare background Sniper solution (BS966G, BioCare, Concord, CA21520, USA). Immunostaining was
performed using specific antibodies against IL-1β (ab9722, Abcam, Cambridge, MA, USA) and NLRP3
(ab17267, Abcam, Cambridge, MA, USA) at room temperature for 1 h. An additional incubation with
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MACH 1 mouse probe (UP537L10, BioCare, Concord, CA21520, USA) for 15 min at room temperature
was performed on sections incubated with the anti-NLRP3 antibody. Samples were then incubated with
a horseradish peroxidase (HRP)-polymer (MRH53BL10, BioCare) for 30 min, stained with Betazoid
DAB chromogen (BDB900B, BioCare, Concord, CA21520, USA), counterstained with hematoxylin,
dehydrated and mounted with distyrene, plasticizer and xylene. Slides were examined using an IX71
microscope (Olympus Australia, Melbourne, Australia).
4.5. Immunofluorescence confocal Microscopy
Immunofluorescence staining was performed on 10% v/v formalin fixed, paraffin embedded
left colon biopsies. Sections were deparaffinized and subjected to 0.01 M citrate buffer (pH 6.0)
antigen retrieval at 121 ◦C for 4 min in a decloaking chamber. Non-specific binding was blocked
by a 1-h incubation in blocking buffer [0.1 mol/L phosphate-buffered saline (PBS)/5% normal
goat serum/0.05% Tween-20] at room temperature in the dark. Immunofluorescence staining was
performed using specific antibodies against NLRP3 (ab16097, Abcam, Cambridge, MA, USA) and
IL-1β (ab9722, Abcam, Cambridge, MA, USA) in the dark, at room temperature for 1 h or alternatively
overnight at 4 ◦C. Sections were then incubated for 1 h in the dark with one or more Alexa Fluor
conjugated-secondary antibodies (Cell Signaling Technology, Danvers, MA, USA). Section were
incubated with 4′,6-diamidino-2-phenylindole Dihydrochloride (DAPI, ThermoFisher Scientific,
Waltham, MA, USA) diluted in PBS and mounted with ProLong Gold Antifade (P36930, ThermoFisher
Scientific, Waltham, MA, USA). Slides were examined using a FV1200 Laser Scanning Confocal Inverted
Microscope (Olympus Australia, Melbourne, Australia).
4.6. Data Analysis
Analysis of qRT-PCR data from colon biopsies was performed using Microsoft Excel and
GraphPad Prism software (version 7.0, GraphPad Software Inc. CA, USA). Colon biopsy gene
expression was compared to a healthy control group and normalized to the housekeeping gene EEF2.
Group difference were tested using paired t tests of log (10) transformed data. Data are presented as
Median Relative Expression (R.E) and interquartile ranges.
Quantitative analysis of immunohistochemistry data was performed using the FIJI version (Dec
2009) of ImageJ software (http://imagej.nih.gov/ij/downloads.html, Rasband, W.S., ImageJ, U.S.
National Institutes of Health, Bethesda, MD, USA), Microsoft Excel and GraphPad Prism (version 7,
GraphPad Software Inc. CA, USA). Briefly, the mean intensity of the DAB signal was measured in
FIJI, optical density was calculated in Excel using log (maximum intensity/mean intensity), where the
maximum intensity of an 8-bit image = 255. Images containing partial tissue were excluded from analysis
because of their potential to bias results by reducing the average optical density. Group differences
and statistical significance were evaluated using a one-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison. Data are presented as mean ± standard deviation.
Colocalization analysis was performed using the Coloc 2 plugin in the FIJI version (Dec 2009) of
ImageJ software (http://imagej.nih.gov/ij/downloads.html, Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA). To ensure consistency, measurements were only
performed on biological relevant regions of interest (ROIs) contained within 400X double stained,
background corrected, confocal images. Manders correlation coefficients (M1 and M2) were used to
determine the co-occurrence of the fluorescence channels and the Pearson’s correlation coefficient
(above the threshold) was used to describe the correlation of the intensity distribution between channels.
2D Histograms generated in Coloc 2 provide an overview of the fluorescent relationship between
channel intensities for homologous pixels. Colocalization data are presented as mean ± standard
deviation. Statistical significance of Pearson’s correlation for the NLRP3/IL-1β double staining was
evaluated in GraphPad Prism (version 7, GraphPad Software Inc. CA, USA), using one-way ANOVA,
followed by Tukey’s multiple comparisons test. In all presented data the significance threshold was set
at p < 0.05.
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Abbreviations
ASC Apoptosis-associated speck-like protein containing a CARD
CASP1 Caspase-1
CD Crohn’s disease
IBD Inflammatory bowel disease
IL-1β Interleukin 1, beta
mRNA Messenger ribonucleic acid
NLRP3 Nod-like receptor family, pyrin domain containing 3
UC Ulcerative colitis
qRT-PCR Quantitative real-time-polymerase chain reaction
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